In the past several weeks, COVID-19 has affected us all personally and professionally in ways we never expected. Some of the changes that have taken place have had a profound effect on covered entities, including drug shortages, 340B enrollment…

To help maintain 340B Program integrity, HRSA has the authority to audit covered entities for compliance with the program requirements. At its core, the audit looks for accuracy of the Office of Pharmacy Affairs Information System (OPAIS), record…

The American Pharmacists Association (APhA) 2020 Annual Meeting & Expo was scheduled to take place March 20-23 in National Harbor, Maryland. Due to the current COVID-19 pandemic, the live event was canceled, but the House of Delegates meeting…

Dear readers, We understand that the news foremost on everyone’s minds at the moment is COVID-19 and the wellbeing of loved ones and the community. Sentry applauds the efforts of everyone working to overcome this challenge, including physicians,…

This month, we take a look at the bracket, which includes the latest MedPAC committee meeting, state legislation that impacts drug prices and 340B, the Supreme Court takes up the ACA case and CMS’ planned survey for covered entities regarding…

With the new year and the new decade now upon us, Sentry is making a concerted effort to attend and present at key conferences throughout 2020, to continue being a voice for covered entities. We began with the 340B Coalition Winter Conference,…

Across the country, health systems of all sizes and complexities use Sentry’s Sentinel® and Sentrex® platforms to manage and optimize participation in the 340B program. The key to successful program compliance is consistent integrity of…

This month, we take a look at the 2021 proposed budget from the White House, new reports about the 340B program from MedPAC and GAO, and review where we stand on several lawsuits, including those regarding the Affordable Care Act and site-neutral…

Orphan drugs are intended to treat rare disease (those affecting fewer than 200,000 people in the US). Many pharmaceutical manufacturers do not develop drugs for these diseases because the potential patient population is so small that the drugs…